YAP1 and neoplasm: Here, we investigated the YAP/TAZ expression of patient-derived HCCs and demonstrated the therapeutic effect of the combination of novel YAP inhibitor (CA3) and sorafenib using a patient-derived 3D multicellular tumor spheroid model.